Skip directly to content

Legal Section

The Healthcare Hub Competitive Grants Process 2017 is now closed for applications. Please see below to find out what's next.

If you enter the Pfizer Healthcare Hub London competitive grant process (CGP):

  • You agree to keep Pfizer’s sensitive commercial information confidential.

If you are shortlisted to pitch as part of the CGP:

  • You agree we can share your elevator pitch with our colleagues throughout Pfizer
  • You agree we can promote your involvement with the pitch event to internal and external stakeholders
  • You agree to engage with appropriate due diligence to be carried out by Pfizer or a nominated third party
  • We agree you can share your engagement with us in your own communications

If you are selected:

  • Pfizer will make no claims on any IP produced during your engagement
  • Pfizer will not purchase or acquire equity in your company during your engagement with the hub
  • Pfizer will not purchase or acquire debt issued by your company during your engagement with the hub
  • Pfizer will not seek to promote or sell its products through your company during your engagement with the hub.

Pfizer Healthcare Hub Collaboration 2017: Competitive Grant Process Pfizer Healthcare Hub London (PHHL) Collaboration 2017: Competitive Grant Process (CGP) - “the Process”

OFFICIAL PHH CGP RULES

NO PURCHASE OR PAYMENT NECESSARY TO ENTER OR TO WIN.  NO APPLICANT WILL BE ENCOURAGED TO PREFERENTIALLY PROMOTE or MARKET ANY PFIZER PRODUCTS OR SERVICES THROUGH THIS COLLABORATION.

  1. Pfizer
    1. The CGP is being organized and funded by Pfizer Limited whose registered office is at Ramsgate Road, Sandwich, Kent CT13 9NJ (“Pfizer”).
  2. The Competitive Grant Process
    1. The title of the Competitive Grant Process is Pfizer Healthcare Hub Collaboration 2017 (“PHH CGP”).
  3. How to enter
    1. The PHH CGP will open at 09:00 AM BST on Thursday 6th April 2017 (the "Opening Date"), and close at 11:59 PM BST Sunday 30th April 2017 (the "Closing Date").
    2. All PHH CGP entries must be received by Pfizer by the Closing Date. All PHH CGP entries received after the Closing Date are automatically disqualified.
    3. To enter the PHH CGP:
      1. Apply to the PHH CGP online by completing and submitting the online application form on the website by the Closing Date.
      2. Your submission must demonstrate the capabilities and functionality of the proposed innovation or solution and where required by law must demonstrate a valid CE mark in respect of any devices sold, manufactured or distributed by you which form part of your submission.
    4. There is no purchase necessary and there is no charge to register for use of the Website.
    5. Pfizer will not accept responsibility for PHH CGP entries that are lost, mislaid, damaged or delayed in transit, regardless of cause, including, without limitation, as a result of any equipment failure, technical malfunction, systems, satellite, network, server, computer hardware, software failure of any kind or errors in and/or failure of the Website.
    6. By submitting a PHH CGP application, you are agreeing to be bound by these terms and conditions.
  4. Eligibility
    1. The PHH CGP is only open to applications from entities with a current active UK company or UK charitable registration (“Applicant(s)”).
    2. Employees of Pfizer or any of its affiliates, and/or any other individual or entity associated with the development, judging, or administration of the PHH CGP as well as members of such persons' immediate families (spouses, children, siblings, parents), and persons living in the same household as such persons, whether or not related, are not eligible to participate in the PHH CGP.
    3. By participating in the PHH CGP, you agree to provide any information that may be required by Pfizer in order to comply with its legal, corporate policy, compliance and/or regulatory obligations.
    4. Applicants to the PHH CGP acknowledge and accept that all information submitted to Pfizer under the PHH CGP application process will be considered by Pfizer as constituting non-confidential disclosures.
  5. Winner selection and evaluation criteria
    1. Initial judging will be conducted by a panel of Pfizer Healthcare Hub colleagues who will select up to 10 finalists from all PHH CGP applications.
    2. The 10 finalists will be invited to pitch to and network with Pfizer colleagues and invited external partners at Pfizer’s offices in Tadworth, Surrey on 18th May 2017. A review of each Applicant by a panel of industry experts will also take place on this date.
    3. The panel of industry experts referred to above will score and rank the finalists. Up to 3 successful Applicants will be selected from the 10 finalists.
    4. Pfizer will undertake any required due diligence on the top three ranked Applicants and will develop draft collaboration plans (including any share of the $70,000 competitive grant fund). In the event due diligence cannot be completed or where a collaboration plan and accompanying agreement cannot be reached with any of the top three ranked Applicants, Pfizer reserves the right to offer the place to any lower ranked Applicant 
    5. The decision of Pfizer OR the judges nominated by Pfizer is final and no correspondence or discussion will be entered into.
  6. The award(s)

    Support and funding up to $70,000 (seventy thousand US dollars) will be available as follows:

    1. The successful Applicants will have the opportunity to draw on Pfizer’s expertise in the healthcare arena for a period of 12 months (the “Collaboration Period”) and to bid for a share of $70,000 for identifiable projects during the Collaboration Period.
    2. The distribution of funding will be based on the following evaluation criteria:
      • Creativity and innovation
      • Potential patient or healthcare provider impact
      • Overall design and intuitiveness of the solution
      • Excellence of the business planning
      • Feasibility of implementation
      • Identifiable projects for the capital allocation and measurable outcomes.
    3. Successful Applicants will also be given the opportunity to receive mentorship and coaching from Pfizer nominated industry experts to support development and execution of their business plans.
    4. Finalists and successful Applicants may be featured in internal Pfizer marketing and in external Pfizer communications throughout the Collaboration Period. Winners may also receive global attention from organisations across the healthcare landscape and have the opportunity to be announced at various conferences throughout the Collaboration Period. There may also be the opportunity to access other Pfizer grants, competitions and schemes throughout the Collaboration Period.
    5. The support and/or funding provided by Pfizer under the PHH CGP is not transferable to any third party.
    6. Applications under the PHH CGP are not intended to, nor shall they be deemed to, establish any employment, sub-contracting, partnership or joint venture between any of the parties, or constitute any party the agent of another party. No party shall have authority to make representations, act in the name or on behalf of, or otherwise to bind any other party.
  7. Representations, Warranties and Indemnities

    By participating in the PHH CGP, each Applicant represents and, warrants as follows:

    1. The Applicant is authorized to submit the entry to the PHH CGP on behalf of his or her registered company or charity;
    2. The Applicant is eligible to participate in the PHH CGP in accordance with the eligibility criteria set out in these Rules and any other criteria which may be stipulated on the Website;
    3. The Applicant’s submission is not the subject of any actual or threatened litigation or claim in any jurisdiction;
    4. The submission does not and will not violate or infringe upon the intellectual property rights, privacy rights, publicity rights, or other legal rights of any third party in any jurisdiction;
    5. The submission does not and will not contain any harmful computer code (sometimes referred to as "malware," "viruses" or "worms"); and
    6. The submission, and the Applicant’s use of the submission, does not and will not violate any applicable laws or regulations, including, without limitation, applicable export control laws and regulations of the U.S., U.K, and other jurisdictions. If the submission includes any third party works (such as third party content or open source code), the Applicant must be able to provide, upon Pfizer's request, all appropriate licenses and releases for such third party works. In the event the Applicant cannot provide all required licenses and releases, Pfizer reserves the right, in its sole discretion, to disqualify the submission.
    7. Applicants will indemnify, defend, and hold harmless Pfizer from and against all third party claims, actions, or proceedings of any kind and from any and all damages, liabilities, costs, and expenses relating to or arising from the Applicant’s submission, or any breach or alleged breach of any of the representations and warranties of the Applicant, and/or from and against any loss, liability, damages, costs and expenses that Pfizer may incur as a result of any claim made against Pfizer for actual or alleged infringement of a third party's intellectual property rights arising out of or in connection with the Applicant’s submission.
    8. Pfizer reserves the right to disqualify any submission that Pfizer, in its sole discretion, deems to violate these Rules.
  8. Announcement regarding successful Applicants
    1. The PHH CGP successful Applicants will be informed on 27th June, using the telephone number or email address provided within the PHH CGP entry. Pfizer is not responsible for e-mail or other communication problems of any kind. If, despite reasonable efforts, a potential winner does not respond within ten (10) working days of the first notification attempt, such potential winner will forfeit their PHH CGP collaborative opportunity and an alternate winner may be selected. If any potential winner is found to be ineligible, or if has not complied with these Rules or declines the collaborative opportunity for any reason prior to award, such potential winner will be disqualified and an alternate winner may be selected. Pfizer may, but is not obliged to, contact any of the Applicants ranked by the industry expert panel on 18th May 2017 to offer collaborative opportunities in the event that less than three winners accept the collaborative opportunity.
  9. Limitation of liability
    1. Insofar as is permitted by law, Pfizer, its agents or distributors will not in any circumstances be responsible or liable to compensate successful or unsuccessful Applicants or accept any liability for any loss, damage, personal injury or death occurring as a result of taking up the award except where it is caused by the negligence of Pfizer, its agents or distributors or that of their employees.
    2. Pfizer makes no warranty, representation, or guarantee, express or implied, in fact or in law, with respect to any award, including, without limitation, regarding such award's suitability or fitness for a particular purpose.
    3. In the event an insufficient number of eligible entries are received or Pfizer is prevented from awarding the funding and/or support or continuing with the PHH CGP as contemplated herein by any event beyond its control, Pfizer shall have the right to modify, suspend, or terminate the PHH CGP.  If the PHH CGP is terminated in such circumstances, Pfizer may (if reasonably possible and in its sole and absolute discretion) select a winner from all eligible, valid entries received as of the date of the event giving rise to the termination.
  10. Data protection and publicity
    1. By completing and submitting an application for the PHH CGP, Applicants agree that any personal information provided by Applicants will be collected, held on a database (either within or outside the EEA) and processed by or on behalf of Pfizer to administer and manage any matters relating to the PHH CGP and to solicit interest in Pfizer’s future activities or initiatives.
    2. As Pfizer is a global organisation it may also transfer such information to other affiliates and/or any third parties providing services to Pfizer, which may be established in jurisdictions outside the European Economic Area (including the USA), for the purpose of storage, use and public disclosure of such information and/or to comply with codes of practice or laws applicable in other jurisdictions to Pfizer and/or its affiliates. In such jurisdictions privacy laws may be less strict than in the UK.  However, Pfizer will always employ appropriate technical security measures to protect personal information provided to us to the same specification as defined in the EU law and to ensure that it is not accessed by unauthorised persons. Applicants and individuals may contact Pfizer at any time by writing to us at IPC 1-1, Pfizer Limited, Walton Oaks, Dorking Road, Walton on the Hill, Surrey, KT20 7NS, United Kingdom to correct any mistakes or request deletion of personal information.
    3. By participating in the PHH CGP, in addition to any other rights granted within these Rules or which may be granted in any other agreement entered into between Pfizer and any Applicant, each Applicant hereby irrevocably (i) grants to Pfizer the right to use such Applicant's name, likeness, image, and biographical information in any and all media for any purpose, including, without limitation, advertising and promotional purposes relating to the PHH CGP and (ii) releases Pfizer from any liability with respect thereto.
    4. No Applicant may use the name or logo of Pfizer in any publicity related to a submission or any product resulting from a submission without Pfizer’s prior express written consent. If an Applicant is invited to pitch on 18th May 2017, the applicant may publicly state that its organisation is a finalist in the Pfizer Healthcare Hub London Competitive Grants Process 2017” and will have a non-transferable revocable right for a limited period of 12 months only to display the Pfizer Healthcare Hub London Logo on a website which is approved by Pfizer. The Applicant agrees not to use the Pfizer Logo or make false or misleading statements about its involvement in the PHH CGP. Winners may have further permissions granted on a case by case basis to be agreed in writing with Pfizer during the Collaboration Period.
  11. Reporting
    1. Pfizer may disclose the details of the PHH CGP and these Rules, and any payment or transfer of value (including details of the awards by Pfizer to a Healthcare Professional (“HCP”) or hospital pursuant to the administration of the PHH CGP (each such payment or transfer of value, a “Reportable Event”), to a governmental body to comply with applicable transparency laws, rules, or regulations. Such details may include (but may not be limited to) an Applicant’s or winner’s name, contact details and the description of Reportable Event. If shortlisted to pitch, Applicants will be required to supply certain information to Pfizer including without limitation whether any HCP, Government Official or hospital was involved in the entry and preparation of the submission, or certify that none were. Such information must be provided in an accurate and timely manner. Full compliance with the terms of this Reporting section and all other terms of these Rules is a condition precedent to any Applicant receiving an award. "Government Official" includes any NHS healthcare professional, elected or appointed government official and any officer, employee or person acting for or on behalf of any of the following: local or central government; a public body (including international bodies); and a political party or candidate for public office (including election candidates, party members and administrative staff employed by political parties)
    2. During the Collaboration Period and for a period of three years after any final payment from Pfizer has been made pursuant to the PHH CGP, the Applicant agrees to promptly arrange for Pfizer and its auditors to have such access to records relating to the arrangements covered by the PHH CGP as they may reasonably require in order to verify the propriety of any payments (including disbursements, expenses or charges) proposed or made to the Applicant.
  12. Intellectual Property Rights

    Pfizer retains title and full ownership to all Intellectual Property Rights which:

    1. Were lawfully possessed by Pfizer prior to receiving a PHH CGP submission from an Applicant and/or
    2. Are or have been independently developed by employees, consultants or agents of Pfizer. Applicants acknowledge that Pfizer may be independently developing concepts or applications similar or identical in nature to the submission or elements of the submission and agree that they have no claims to such Intellectual Property Rights.
    3. Intellectual Property Rights” means all copyrights, trade secrets, trademarks, patent rights, Know-How and any and all other intellectual property or proprietary rights now known or hereafter recognized in any jurisdiction. “Know-How” means any invention, discovery, development, data, information, process, method, technique, technology, result, or other know-how, whether or not patentable, and any embodiments of any of the foregoing.
    4. Pfizer does not claim or assert any rights of ownership in an Applicant’s PHH CGP entry, accompanying materials, intellectual property and/or company.
  13. Right of First Negotiation

    Pfizer makes no claim and asks for no rights to first negotiation. Applicants and winners are free to sell their equity to, trade with or work with any other company, charity or persons at any time, including during the Collaboration Period.

  14. General
    1. If there is any reason to believe that there has been a breach of these terms and conditions, Pfizer may, at its sole discretion, reserve the right to exclude Applicants from participating in the PHH CGP.
    2. Pfizer reserves the right to hold void, suspend, cancel, or amend the PHH CGP where it becomes necessary to do so.
    3. These terms and conditions shall be governed by English law, and the parties submit to the non-exclusive jurisdiction of the courts of England and Wales.
Back to top